ARPA-H Launches ASCENT-IBO Initiative for Ibogaine Clinical Research

WASHINGTON – The Advanced Research Projects Agency for Health (ARPA-H) has launched a federal research opportunity aimed at accelerating clinical evaluations of ibogaine for Opioid Use Disorder (OUD).

Titled ASCENT-IBO, short for Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder, the program provides targeted federal backing for combined Phase I and Phase II clinical trials. The initiative follows Executive Order 14401, which directed federal research agencies to expand clinical investigations into neuroplastogen-based interventions and emerging mental health treatments.

Derived from the root bark of the African iboga shrub, ibogaine has drawn clinical interest for its ability to rapidly suppress severe opioid withdrawal symptoms and craving behaviors. However, safety concerns, specifically cardiotoxicity risks tied to QT interval prolongation, have historically limited human trials within the United States, leaving ibogaine classified as a Schedule I substance.

Under the ARPA-H special notice, funding priority will be directed toward commercial entities, academic institutions, and clinical networks capable of designing rigorous safety protocols. Key program requirements emphasize continuous cardiac monitoring, dose optimization, and structured protocols to mitigate cardiovascular risks.

The federal push bridges a gap created by state-level research initiatives. While states like Texas have allocated public funds to evaluate ibogaine, domestic clinical research has lacked centralized oversight and formal paths toward Food and Drug Administration (FDA) approval.

By establishing structured trial criteria, ARPA-H intends to transition observational data collected at international clinics into standardized, U.S.-regulated clinical trials. Applicants submitted solution summaries to the Proactive Health Mission Office ahead of the fall review cycle, with selected performers tasked with building clear pathways toward future Phase III clinical evaluations.

The deployment of federal research capital indicates a shift in how regulatory bodies view high-risk, high-effect botanical compounds. As traditional maintenance therapies face high relapse rates, federal agencies are examining whether structured clinical trial frameworks can safely isolate the therapeutic potential of complex psychedelic molecules.

Overall, the activation of federal funding through ARPA-H signals an institutional shift in how regulatory frameworks approach high-risk, high-potency psychedelic compounds. For decades, ibogaine existed on the regulatory periphery, utilized primarily in international clinics operating outside FDA jurisdiction. By creating a structured research pathway under federal oversight, healthcare agencies are signaling that clinical utility, when supported by rigorous risk-mitigation data, can warrant the re-evaluation of long-restricted molecules.

This initiative also highlights a changing dynamic between state legislative momentum and federal health agencies. Early funding efforts in state legislatures created political pressure, but lacked the centralized regulatory architecture required to move a Schedule I compound through FDA IND channels. ARPA-H’s involvement fills this structural gap, providing the clinical infrastructure, cardiac monitoring protocols, and trial design standards needed to evaluate ibogaine alongside conventional medical paradigms.